SCHEMBL7935759

SCHEMBL7935759

Cc1ccc2oc(C(=O)Nc3ccnc(CNc4cccnc4N)c3)c(C)c2c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 15/20 0.51
NPC1 O15118 12/20 0.51
MAPT P10636 3/20 0.51
KDM4E B2RXH2 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HPGD P15428 2/20 0.51
TSHR P16473 2/20 0.51
HSD17B10 Q99714 2/20 0.51
TP53 P04637 1/20 0.51
TDP1 Q9NUW8 1/20 0.46
GAA P10253 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
DGAT1 O75907 1/20 0.44
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7943409 0.92 RAB9A (0.45) RAB9ANPC1MAPTKDM4ESMN1; SMN2
SCHEMBL7946785 0.91 RAB9A (0.50) RAB9ANPC1MAPTKDM4ESMN1; SMN2
SCHEMBL7945393 0.91 RAB9A (0.58) RAB9ANPC1MAPTKDM4ESMN1; SMN2
SCHEMBL7944977 0.91 RXFP1 (0.50) RAB9ANPC1MAPTSMN1; SMN2MEN1
SCHEMBL7945003 0.91 RAB9A (0.56) RAB9ANPC1MAPTKDM4ESMN1; SMN2
SCHEMBL7943411 0.90 NPC1 (0.57) RAB9ANPC1MAPTKDM4ESMN1; SMN2
SCHEMBL7940970 0.88 BACE1 (0.56) RAB9ANPC1MAPTKDM4ESMN1; SMN2
SCHEMBL7942886 0.85 DGAT1 (0.49) RAB9ANPC1MAPTKDM4ESMN1; SMN2
SCHEMBL7934104 0.83 RAB9A (0.47) RAB9ANPC1MAPTKDM4ESMN1; SMN2
SCHEMBL7942072 0.81 NAMPT (0.49) RAB9ANPC1MAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 RAB9A 1287/4885NPC1 431/4885MAPT 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.